Myositis clinical trials at UCSD
1 in progress, 0 open to eligible people
Showing trials for
CTX112 in Adult Subjects With Refractory Autoimmune Disease
Sorry, not currently recruiting here
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
La Jolla, California and other locations
Our lead scientists for Myositis research studies include Brian Pedersen, MD.
Last updated: